InMed Pharmaceuticals (INM) Peer Comparison

$1.36

$0.03 (2.26%)

As on 04-Sep-2026 13:05EDT

Market cap

$7 Mln

Revenue (TTM)

$664 Mln

P/E Ratio

--

P/B Ratio

1.1

Div. Yield

0 %

Edit

	InMed Pharmaceuticals (INM)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)
Market cap ($ Mln)	7	5,809	2,167	3,678	345
Revenue ($ Mln)	664	--	312	66	0
Net Profit ($ Mln)	-9.91	-409.20	314.11	-164.66	-37.54
Net Margin (%)	-1.49	--	100.84	-248.83	134,079.79
RoE (%)	-85.98	-44.86	52.52	-17.68	-79.49
Price to Earnings	--	--	7.14	--	--
Price-To-Book	1.12	4.83	3.57	4.48	9.49

Cashflow
Ratios

Cashflow ($ Mln)

	InMed Pharmaceuticals (INM)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)
Cash From Operating Activities	-7.77	-279.12	135.66	-131.30	-29.06
Cash Flow from Investing Activities	--	218.00	-32.77	87.75	-2.19
Cash from Financing Activities	12.27	117.11	-106.11	14.08	43.88
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	InMed Pharmaceuticals (INM)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)
ROCE (%)	-49.14	-51.11	51.61	-13.12	-67.28
ROE (%)	-85.98	-44.86	52.52	-17.68	-79.49
ROA (%)	-68.08	-27.75	42.65	-11.64	-60.11
EBIT Margin (%)	-1.48	--	54.20	-304.58	133,972.64
Net Margin (%)	-1.49	-4,612.13	100.84	-248.83	134,079.79
Cash Profit Margin (%)	0.00	--	0.00	0.00	3.35

Growth Ratios

	InMed Pharmaceuticals (INM)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)
Revenue Growth (%)	13,390.59	--	19.76	101.28	-100.20
EBIT Growth (%)	-23.36	3.41	151.91	23.59	-26.93
Net Profit Growth (%)	-19.26	-47.07	418.03	0.61	-26.91
EPS Growth (%)	-8,841.48	-34.29	434.98	2.53	-6.40
Book Value Growth (%)	-81.34	55.33	96.66	-13.08	12.47

Valuation Ratios

	InMed Pharmaceuticals (INM)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)
Price / Earnings	-0.80	-10.27	7.70	-6.98	-11.41
Price / Book Value	0.36	6.11	3.81	1.06	6.66
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	1.05	-8.80	14.79	-4.24	-9.61
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	InMed Pharmaceuticals (INM)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)
Debt to Equity	0.00	0.00	0.00	0.00	0.00
Short term debt to equity ratio	0.06	0.00	0.03	0.01	0.00
Current Ratio	3.11	21.02	5.42	12.77	6.72
Quick Ratio	3.11	21.02	4.97	12.63	6.72
Interest Coverage	-485.88	--	17.75	-11.19	--

Operating Efficiency Ratios

	InMed Pharmaceuticals (INM)	Xenon Pharmaceuticals (XENE)	Aurinia Pharmaceuticals (AUPH)	Abcellera BiologicsÂ Inc (ABCL)	DiaMedica Therapeutics (DMAC)
Debtors to sales (%)	0.00	18.28	13.21	144.21	0.00
Asset Turnover	45.60	0.00	0.42	0.05	0.00
Receivable days	41.24	69.15	50.32	596.85	--
Inventory Days	169.94	--	474.76	40.15	--
Payable days	76.79	643.10	47.52	377.52	--
Cash Conversion Cycle	134.40	--	477.57	259.48	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly